December 22, 2021 09:43 AM EST

Allakos drops a pair of duds on patient-reported symptom relief for GI disease, vaporizing billions off its value

Kyle Blankenship

Targeting overactive white blood cells known as eosinophils has become a hot drug target with multiple approvals in recent years. One company with big platform …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Allakos drops a pair of duds on patient-reported symptom relief for GI disease, vaporizing billions off its value

Kyle Blankenship

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Merus’ Phase 2 overall survival data reach ‘home run’ scenario — analyst

Volastra unveils first human data of its solid tumor drug target

Geoffrey Porges exits Schrödinger with CFO swap; A new board seat for AstraZeneca's Pascal Soriot

Roche confirms overall survival benefit for PI3K inhibitor in breast cancer

The ‘MAHA report’: Four key takeaways on vaccines, medicine and the pharma industry

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Al­lakos drops a pair of duds on pa­tient-re­port­ed symp­tom re­lief for GI dis­ease, va­por­iz­ing bil­lions off its val­ue

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Allakos drops a pair of duds on patient-reported symptom relief for GI disease, vaporizing billions off its value